TZ4M, a 2,4-thiazolidinedione (TZD)-based anti-ADV agent, exhibits neuroprotective effects and acetylcholinesterase (AChE) inhibition in human plasma. It enhances memory and cognitive function in adult rats within a scopolamine-induced Alzheimer-type model [1].

In a rat model, TZ4M (2, 3 mg/kg; intraperitoneal injection; once daily for 8 days) inhibited scopolamine (3 mg/kg; intraperitoneal injection)-induced hippocampal neuronal damage and apoptosis in both hippocampal neurons and cortical proteins, as well as increased the number of mAChR M1 receptors in the DG region and CA1 neurons of the hippocampus and cortex [1]. TZ4M was predicted to be BBB positive by CB-ligand-BBB, a requisite for AChE inhibition [1].